Skip to main content
SpringerLink
Log in

The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future)

  • Review
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Over the past quarter-century, liver transplantation (LT) has been established as a durable therapy for all forms of end-stage liver disease. LT appears ideally suited for hepatocellular carcinoma (HCC), as it involves complete oncologic resection and correction of the underlying liver dysfunction. Since LT based on the Milan criteria has been shown to provide good diseasefree survival, LT is considered the optimal treatment for small HCC, especially in patients with underlying chronic liver disease. However, because there is a severe shortage of organ donors, not all patients in need can be offered LT. Transplant listing criteria must simultaneously determine the greatest number of suitable candidates for LT while rejecting the smallest number of those who could benefit from LT. The amended model for end-stage liver disease allocation policy has had a positive effect on liver transplant candidates with HCC, and their number has been increasing significantly over the past several years. To minimize dropout from the waiting list, the treatment of HCC with procedures such as chemoembolization, radiofrequency ablation, or ethanol injection in patients awaiting LT have become widespread. It is currently accepted that liver resection is the best option for the treatment of small HCC when liver function is well preserved, and that LT is preferred when liver function is severely impaired (Child-Pugh class B or C). However, the question arises as to what is the best option for Child-Pugh class A patients with early HCC eligible for both resection and LT, especially in Western countries. HCC is a major indication for living donor liver transplantation (LDLT), because the risk of dropout while waiting is negligible. Extension of the Milan criteria in the setting of LDLT may offer more patients a potentially curative treatment without reducing the donor pool of organs for patients on the waiting list with nonmalignant liver disease. However, imprudent expansion of the selection criteria may result in more patients with HCC being cured at the expense of a higher incidence of recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, et al. Increased survival of cirrhotic patients with hepatocellular carcinoma detected during surveillance. Gastroenterology 2004;126:1005–14.

    Article  PubMed  Google Scholar 

  2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 1996;334:693–9.

    Article  PubMed  CAS  Google Scholar 

  3. Ringe B Pichlmayr R, Wittekind C, Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991;15:270–85.

    Article  PubMed  CAS  Google Scholar 

  4. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhosis. Ann Surg 1993;218:145–51.

    Article  PubMed  CAS  Google Scholar 

  5. Stone MJ, Fulmer JM, Klintmalm GB. Transplantation for primary hepatic malignancy. In: Busuttil RW, Klintmalm GB, editors. Transplantation of the liver. Second Ed. Philadelphia: Saunders; 2005. p. 211–32.

    Google Scholar 

  6. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999;19:311–22.

    Article  PubMed  CAS  Google Scholar 

  7. Ravaioli M, Ercolani G, Cescon M, Vetrone G, Voci C, Grigioni WF, et al. Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. Liver Transpl 2004;10:1195–202.

    Article  PubMed  Google Scholar 

  8. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434–40.

    Article  PubMed  CAS  Google Scholar 

  9. Shetty K, Timmins K, Brensinger C, Furth EE, Rattan S, Sun W, et al. Transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004;10:911–8.

    Article  PubMed  Google Scholar 

  10. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005;40:225–35.

    Article  PubMed  Google Scholar 

  11. Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol 2003;21:4329–35.

    Article  PubMed  Google Scholar 

  12. United Network for Organ Sharing. About the MELD/PELD calculator. http://www.unos.org/resources/MeldPeldCalculator.asp?index=97. Accessed: 19 October 2007.

  13. Kogure T, Ueno Y, Kawagishi N, Kanno N, Yamagiwa Y, Fukushima K, et al. The model for end-stage liver disease score is useful for predicting economic outcomes in adult cases of living donor liver transplantation. J Gastroenterol 2006;41:1005–10.

    Article  PubMed  Google Scholar 

  14. United Network for Organ Sharing. Policy 3.6 organ distribution: allocation of livers. Revised December 14, 2006. http://www.unos.org/policiesandbylaws/policies.asp?resources=true. Accessed: 19 October 2007.

  15. Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez-Luna H, et al. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl 2004;10:36–41.

    Article  PubMed  Google Scholar 

  16. Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R. Results of the first year of the new liver allocation plan. Liver Transpl 2004;10:7–15.

    Article  PubMed  Google Scholar 

  17. Sharma P, Harper AM, Hernandez JL, Heffron T, Mulligan DC, Wiesner RH, et al. Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation. Am J Transpl 2006;6:1957–62.

    Article  CAS  Google Scholar 

  18. Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and cost-effectiveness perspective. Hepatology 2001;33:1073–9.

    Article  PubMed  CAS  Google Scholar 

  19. Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation. A prospective study. Ann Surg 2004;240:900–9.

    Article  PubMed  Google Scholar 

  20. Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003;9:557–63.

    Article  PubMed  Google Scholar 

  21. Yao FY, Kinkhabwala M, LaBerge JM, Bass NM, Brown R Jr, Kerlan R, et al. The impact of preoperative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant 2005;5:795–804.

    Article  PubMed  Google Scholar 

  22. Lesurtel M, Mullhaupt B, Pestalozzi BC, Pfammatter T, Clavien PA. Transarterial chemoembolization as a bridge of liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transpl 2006;6:2644–50.

    Article  CAS  Google Scholar 

  23. Belghiti J, Cortes A, Abdalla EK, Regimbeau JM, Prakash K, Durand F, et al. Resection prior to liver resection for hepatocellular carcinoma. Ann Surg 2003;238:885–93.

    Article  PubMed  Google Scholar 

  24. Hwang S, Lee SG, Moon DB, Ahn CS, Kim KH, Lee YJ, et al. Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma. Liver Transpl 2007;13:741–6.

    Article  PubMed  Google Scholar 

  25. Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis. Ann Surg 2003;238:508–19.

    Article  PubMed  Google Scholar 

  26. Figueras J, Jaurrieta E, Valls C, Ramos E, Serrano T, Rafecas A, et al. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients; outcomes based on indicated treatment strategy. J Am Coll Surg 2000;190:580–7.

    Article  PubMed  CAS  Google Scholar 

  27. Shabahang M, Franceschi D, Yamashiki N, Reddy R, Pappas PA, Aviles K, et al. Comparison of hepatic resection and hepatic transplantation in the treatment of hepatocellular carcinoma among cirrhotic patients. Ann Surg Oncol 2002;9:881–6.

    Article  PubMed  Google Scholar 

  28. Margarit C, Escartin A, Castells L, Vargas V, Allende E, Bilbao I. Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl 2005;11:1242–51.

    Article  PubMed  Google Scholar 

  29. Bigourdan JM, Jaeck D, Meyer N, Meyer C, Oussoultzoglou E, Bachellier P, et al. Small hepatocellular carcinoma in Child A cirrhotic patients: hepatic resection versus transplantation. Liver Transpl 2003;9:513–20.

    Article  PubMed  Google Scholar 

  30. Cillo U, Vitale A, Brolese A, Zanus G, Neri D, Valmasoni M, et al. Partial hepatectomy as first-line treatment for patients with hepatocellular carcinoma. J Surg Oncol 2007;95:213–20.

    Article  PubMed  Google Scholar 

  31. Ishizaki Y, Yoshimoto J, Sugo H, Miwa K, Kawasaki S. Hepatectomy using the traditional Péan clamp crushing technique under intermittent Pringle maneuver. Am J Surg 2008 (in press).

  32. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantations. Ann Surg 2002;235:373–82.

    Article  PubMed  Google Scholar 

  33. Kawasaki S, Makuuchi M, Matsunami H, Hashikura Y, Ikegami T, Nakazawa Y, et al. Living related liver transplantation in adults. Ann Surg 1998;227:269–74.

    Article  PubMed  CAS  Google Scholar 

  34. Cheng SJ, Pratt DS, Freeman RB Jr, Kaplan MM, Wong JB. Living-donor versus cadaveric liver transplantation for nonresectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis. Transplantation 2001;72:861–8.

    Article  PubMed  CAS  Google Scholar 

  35. Kawasaki S. Living-donor liver transplantation for hepatocellular carcinoma. Hepatogastroenterology 2002;49:53–5.

    PubMed  Google Scholar 

  36. Todo S, Furukawa H; Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma. Experience in Japan. Ann Surg 2004;240:451–61.

    Article  PubMed  Google Scholar 

  37. Hwang S, Lee SG, Joh JW, Suh KS, Kim DG. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 2005;11:1265–72.

    Article  PubMed  Google Scholar 

  38. Takada Y, Ueda M, Ito T, Sakamoto S, et al. Living donor liver transplantation as a second line therapeutic strategy for patients with hepatocellular carcinoma. Liver Transpl 2006;12:912–9.

    Article  PubMed  Google Scholar 

  39. Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, Aishima S, Terashi T, et al. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation 2007;83:893–9.

    Article  PubMed  Google Scholar 

  40. Middleton PF, Duffield M, Lynch SV, Padbury RT, House T, Stanton P, et al. Living donor liver transplantation—adult donor outcomes: a systematic review. Liver Transpl 2006;12:24–30.

    Article  PubMed  Google Scholar 

  41. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007;7:2587–94.

    Article  PubMed  CAS  Google Scholar 

  42. Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007;246:502–11.

    Article  PubMed  Google Scholar 

  43. Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2004;127:S268–76.

    Article  PubMed  Google Scholar 

  44. Tamura S, Sugawara Y, Kaneko J, Kishi Y, Akamatsu N, Yamashita N, et al. Live donor liver transplantation for hepatocellular carcinoma (abstract 832). Am J Transplant 2006;6(Suppl 2):348.

    Google Scholar 

  45. Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 2004;127:S277–82.

    Article  PubMed  Google Scholar 

  46. Iwatsuki S, Dvorchik I, Marsh JW, Madariaga JR, Carr B, Fung JJ, et al. Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 2000;191:389–94.

    Article  PubMed  CAS  Google Scholar 

  47. Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001;233:652–9.

    Article  PubMed  CAS  Google Scholar 

  48. Neumaier M, Gerhard M, Wagener C. Diagnosis of micrometastasis by amplification of tissue-specific genes. Gene 1995;159:43–7.

    Article  PubMed  CAS  Google Scholar 

  49. Ghossein RA, Rosai J. Polymerase chain reaction in the detection of micrometastasis and circulating tumor cells. Cancer 1996;78:10–6.

    Article  PubMed  CAS  Google Scholar 

  50. Hillaire S, Barbu V, Boucher E, Moukhar M, Poupon R. Albumin messenger RNA as a marker of circulating hepatocytes in hepatocellular carcinoma. Gastroenterology 1994;106:239–42.

    PubMed  CAS  Google Scholar 

  51. Funaki NO, Tanaka J, Seto SI, Kasamatsu T, Kaido T, Imamura M. Hematogenous spreading of hepatocellular carcinoma cells: possible participation in recurrence in the liver. Hepatology 1997;25:564–8.

    Article  PubMed  CAS  Google Scholar 

  52. Komeda T, Fukuda Y, Sando T, Kita R, Furukawa M, Nishida N, et al. Sensitive detection of circulating hepatocellular carcinoma cells in peripheral venous blood. Cancer 1995;75:2214–9.

    Article  PubMed  CAS  Google Scholar 

  53. Ijichi M, Takayama T, Matsumura M, Shiratori Y, Omata M, Makuuchi M. alpha-Fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study. Hepatology 2002;35:853–60.

    Article  PubMed  CAS  Google Scholar 

  54. Marubashi S, Dono K, Nagano H, Sugita Y, Asaoka T, Hama N, et al. Detection of AFP mRNA-expressing cells in the peripheral blood for prediction of HCC recurrence after living donor liver transplantation. Transpl Int 2007;20:576–82.

    Article  PubMed  CAS  Google Scholar 

  55. Jiang SY, Shyu RY, Huang MF, Tang HS, Young TH, Roffler SR, et al. Detection of alpha-fetoprotein-expressing cells in the blood of patients with hepatoma and hepatitis. Br J Cancer 1997;75:928–33.

    PubMed  CAS  Google Scholar 

  56. Lemoine A, Le Bricon T, Salvucci M, Azoulay D, Pham P, Raccuia J, et al. Prospective evaluation of circulating hepatocytes by alphafetoprotein mRNA in humans during liver surgery. Ann Surg 1997;226:43–50.

    Article  PubMed  CAS  Google Scholar 

  57. Suehiro T, Sugimachi K, Matsumata T, Itasaka H, Taketomi A, Maeda T. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein. Cancer 1994;73:2464–71.

    Article  PubMed  CAS  Google Scholar 

  58. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma. A prospective analysis of 227 patients. Cancer 2001;91:561–9.

    Article  PubMed  CAS  Google Scholar 

  59. Shirabe K, Itoh S, Yoshizumi T, Soejima Y, Taketomi A, Aishima S, et al. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma. With special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol 2007;95:235–40.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hepatobiliary-Pancreatic Surgery, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan

    Yoichi Ishizaki & Seiji Kawasaki

Authors
  1. Yoichi Ishizaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seiji Kawasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ishizaki, Y., Kawasaki, S. The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future). J Gastroenterol 43, 18–26 (2008). https://doi.org/10.1007/s00535-007-2141-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-007-2141-x

Key words

Search

Navigation